DisclosureWe earn commission on partner links; ranking is set by our published methodology — not advertisers.
A datestamped record of every material GLP‑1 development: FDA approvals, price changes, provider launches, supply shifts, legal actions, and new research. We update it as it happens.
Litigation over compounded marketing; Zealthy also lost LegitScript certification earlier in 2025. Verify provider standing before enrolling.
Provider legal tracker →CMS Medicare Part D Bridge starts July 1, 2026: $50/month for Foundayo, Wegovy (pill + injection), and Zepbound KwikPen. Replaces the indefinitely-delayed BALANCE model. Major opening for the Medicare-age obesity segment.
Insurance coverage →Eli Lilly topline Phase 3 data: 28.3% average body weight loss at 80 weeks on 12 mg, up to 30.3% in higher-BMI cohorts, the deepest of any GLP-1-class drug. NDA expected end of 2026.
Retatrutide deep-dive →Population-scale compounding lost shortage-exemption protection. Compounded supply contracting; 503A/503B enforcement tightening.
Compounding quality →Manufacturer cash-pay vials remain the cheapest brand-name route. NovoCare Wegovy holds at $499/mo flat.
International + cash-pay pricing →FDA expanded oral semaglutide availability through Weight Watchers Med+, broadening the oral T2D dispensing landscape. See our oral GLP-1 hub.
Oral GLP-1 hub →FDA proposed removing semaglutide, tirzepatide, and liraglutide from the 503B bulks list ("no clinical need"). Comment period closes June 29, 2026. Would bar large-scale compounding even in future shortages.
What the ban means →Real-world data confirms high discontinuation — around two-thirds of people without diabetes stop within a year. The twist: far fewer actually restart (about a third) than say they will. This cycling behaviour is the subject of our lifecycle hub.
GLP-1 lifecycle →Eli Lilly’s first small-molecule oral GLP-1, approved for chronic weight management — no food/water timing restrictions; manufacturable at scale. ~12.4% mean weight loss at 72 weeks (ATTAIN-1). Type 2 diabetes filing expected 2026.
Oral GLP-1 hub →Higher-dose Wegovy approved for adults who tolerate 2.4 mg but plateau. STEP UP trial showed ~5-6 percentage points additional weight loss.
Wegovy HD →Editorial changelog, updated as developments occur. Dates reflect publication or our verification date. Not an exhaustive regulatory record.